Genpharmasec Ltd
04 Nov 2026 12:00 AM
Genpharmasec Ltd consolidated sales up 72.32% on year in Q3FY2026,
Genpharmasec Ltd share price ticked higher by 1.96% to Rs 1.04 after the company`s net profit witnessed a sharp fall of 705.88% to Rs 1.03 crore, while revenue from operations increased sharply by 72.32% to Rs 85.66 crore in Q3FY26 over Q2FY26.
The market capitalization of Trading & Distributors industry group stocks on BSE stood at Rs 62565.47 crore, dropping 14.44%. It has eased by 1.87% over last one week and dipped slightly by 7.96% in last one month while the market capitalization of Genpharmasec Ltd has marginally improved by 7.22% and 0.95% in the same period respectively.
Profit before tax (PBT) of Genpharmasec Ltd stood at Rs 1.58 crore in Q3 FY26, plunging by 297.50% year-on-year, and jumping 507.69% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 161.70% YoY and remaining flat sequentially.
Total expenses soared by 71.35% to Rs 84.7 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1.69 crore, witnessing a sharp rise of 59.43% YoY, while employee benefits expense was at Rs 1.12 crore, easing 0.90% YoY.
For the TTM ended FY26, revenue from operations jumped by 315.01% to Rs 139.94 crore, while net profit tanked by 64.10% to Rs 0.56 crore, compared to previous TTM. EBITDA saw a sharp decline of 231% to Rs 1.94 crore, and PBT tumbled by 56.11% to Rs 0.97 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 17.55 crore in FY26, as against Rs 3.0 crore in FY25.
Genpharmasec Ltd nosedived by 35% in last one year, underperforming the benchmark BSE Sensex which has slipped by 8.41% during the same period.
Genpharmasec Ltd
03 Nov 2026 12:00 AM
Genpharmasec Ltd consolidated sales up 72.32% on year in Q3FY2026,
Genpharmasec Ltd share price ticked higher by 3.03% to Rs 1.02 after the company`s net profit plunged by 705.88% to Rs 1.03 crore, while revenue from operations increased sharply by 72.32% to Rs 85.66 crore in Q3FY26 over Q2FY26.
The market capitalization of Trading & Distributors industry group stocks on BSE stood at Rs 62195.9 crore, retreating 14.44%. It has softened by 3.80% over last one week and fell by 8.38% in last one month while the market capitalization of Genpharmasec Ltd has marginally improved by 3.03% and 2.86% in the same period respectively.
Profit before tax (PBT) of Genpharmasec Ltd stood at Rs 1.58 crore in Q3 FY26, tumbling by 297.50% year-on-year, and surging by 507.69% quarter-on-quarter. EBITDA came in at Rs 1 crore, tanking 161.70% YoY and remaining flat sequentially.
Total expenses soared by 71.35% to Rs 84.7 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1.69 crore, soaring by 59.43% YoY, while employee benefits expense was at Rs 1.12 crore, inching up 0.90% YoY.
For the TTM ended FY26, revenue from operations jumped by 315.01% to Rs 139.94 crore, while net profit witnessed a sharp fall of 64.10% to Rs 0.56 crore, compared to previous TTM. EBITDA tumbled by 231% to Rs 1.94 crore, and PBT collapsed by 56.11% to Rs 0.97 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 17.55 crore in FY26, as against Rs 3.0 crore in FY25.
Genpharmasec Ltd nosedived by 36.25% in last one year, underperforming the benchmark BSE Sensex which has softened by 9.87% during the same period.
Genpharmasec Ltd
11 Aug 2026 12:00 AM
Genpharmasec Ltd consolidated sales down 10.32% on year in Q2FY2026, net profit tumbled by 112.59%,
Genpharmasec Ltd share price slipped 0.94% to Rs 1.05 after the company`s net profit plunged by 112.59% to Rs 0.17 crore, while revenue from operations reduced 10.32% to Rs 49.71 crore in Q2FY26 over Q1FY26.
The market capitalization of Trading & Distributors industry group stocks on BSE stood at Rs 49465.98 crore, easing 9.74%. It has inched up 1.03% over last one week and jumped by 26.61% in last one month while the market capitalization of Genpharmasec Ltd has remained flat
Profit before tax (PBT) of Genpharmasec Ltd stood at Rs 0.26 crore in Q2 FY26, tumbling by 79.20% year-on-year, and tanking 85.95% quarter-on-quarter. EBITDA came in at Rs 1 crore, expanding by 132.00% YoY and crashing by 40.82% sequentially.
Total expenses marginally dropped 8.65% to Rs 49.43 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1.06 crore, jumping 783.33% YoY, while employee benefits expense was at Rs 1.11 crore, inching up 3.74% YoY.
For the TTM ended FY26, revenue from operations advanced 10.88% to Rs 33.72 crore, while net profit tanked by 1017.65% to Rs 1.56 crore, compared to previous TTM. EBITDA saw a sharp decline of 85% to Rs 2.67 crore, and PBT jumped 784% to Rs 2.21 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 3.0 crore in FY26, as against Rs 2.95 crore in FY25.
Genpharmasec Ltd nosedived by 47.50% in last one year, underperforming the benchmark BSE Sensex which has softened by 2.56% during the same period.
Genpharmasec Ltd
11 Aug 2026 12:00 AM
Genpharmasec confirms proper use of Rs 4,845.05 lakh rights issue proceeds,
Genpharmasec Limited confirmed to the BSE that there was no deviation or variation in the use of proceeds from its rights issue, announced on February 21, 2024, which raised Rs 4,845.05 lakh, according to a regulatory filing on August 11, 2026. The company’s Audit Committee reviewed the statement, which detailed the utilization of funds for acquiring equity shares from existing shareholders of Derren Healthcare Private Limited, repaying borrowings, financing working capital, meeting general corporate purposes, and covering issue expenses.
Genpharmasec Ltd
03 Aug 2026 12:00 AM
Genpharmasec to discuss results,
Genpharmasec will hold a meeting of the Board of Directors of the Company on 11 August 2026.
Subscribe for our
newsletter
newsletter
HSL Mobile App